Cardio-oncology for better lymphoma therapy outcomes

Affiliations

¹ Maria Sklodowska-Curie National Institute of Oncology, Krakow 31-113, Poland.
² Maria Sklodowska-Curie National Institute of Oncology, Krakow 31-113, Poland. Electronic address: monika.dlugosz-danecka@lymphoma.edu.pl.
³ Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland.

Comment

Wojciech Jurczak et al. Lancet Haematol. 2020 Apr.

. 2020 Apr;7(4):e273-e275.

doi: 10.1016/S2352-3026(20)30066-1. Epub 2020 Mar 2.

¹ Maria Sklodowska-Curie National Institute of Oncology, Krakow 31-113, Poland.
² Maria Sklodowska-Curie National Institute of Oncology, Krakow 31-113, Poland. Electronic address: monika.dlugosz-danecka@lymphoma.edu.pl.
³ Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland.

No abstract available

Comment on

Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M, Kamphuis JAM, van Rhenen A, Bosman LP, Cramer MJ, Doevendans PA, Teske AJ, Asselbergs FW. Linschoten M, et al. Lancet Haematol. 2020 Apr;7(4):e295-e308. doi: 10.1016/S2352-3026(20)30031-4. Epub 2020 Mar 2. Lancet Haematol. 2020. PMID: 32135128